In this Q&A, Doceree CEO Harshit Jain, MD, explains why AI should inform prescribing decisions, not drive them, and how sales reps own relationships while AI extends reach.
News|Articles|September 21, 2026
EU Pharma Reform: Strategic Implications for US Drugmakers
Author(s)Isobel Barry, Daniel Goodman
The EU's pharma reform makes market protection more conditional. Here is how US drugmakers, especially startups, can adapt and use IP to complement it.
Advertisement
Advertisement
The European Union's (EU) pharmaceutical reform package is expected to be signed into law later in 2026 following extensive consultation, political negotiation and lobbying from stakeholders across the biopharma sector. The package gives rise to new strategic considerations for drugmakers because market protection is becoming more conditional on alignment with the EU’s policy objectives.
Related to this article
In this week's Pharma Pulse, the EU Council adopts the "pharma package," Commerce details 0% tariffs for certain drugs and Sharp expands autoinjector assembly capacity.
Waltz Health and Fresenius Kabi will offer three biosimilars through a direct-to-payer model that bypasses traditional wholesaler and PBM rebate channels.
HDA's Kala Shankle says a federal licensure baseline could bring real efficiency gains for wholesale distributors and 3PLs, but only if state requirements align and every stakeholder moves on the same timeline.
With HRSA's approval window now closed, attention turns to whether health system pharmacies can reconcile rebates at scale before the pilot's Jan. 1 start.
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
CMS says 40 states and Puerto Rico have signed on to the GENEROUS Model, which applies MFN pricing to Medicaid drugs through state-invoiced rebates.
The White House said Medicaid programs in all 50 states, D.C. and Puerto Rico now receive MFN prices, with nearly $65 billion in savings over a decade.
Advertisement
Advertisement